Analyst consensus rating
Avalyn Pharma Analyst Rating: none
Direct answer
Avalyn Pharma's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $61.80.
Forecast evidence checked November 12, 2026.
Get free Avalyn Pharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $31.62
- Average price target
- $61.80
- High price target
- $80.00
- Low price target
- $52.00
- Low target gap
- +64.5%
- Target upside
- +95.4%
- High target gap
- +153%
- Target range width
- 88.6%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- November 12, 2026
- Valid through
- November 19, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Avalyn Pharma?
Avalyn Pharma has a verified none consensus. The same dataset has an average price target of $61.80.
How far are Avalyn Pharma's low and high targets from the recorded price?
The low target implies +64.5%, while the high target implies +153%.
How many analysts are included in Avalyn Pharma's consensus?
The verified consensus includes 5 analysts.
How is Avalyn Pharma's target upside or downside calculated?
The average target of $61.80 is divided by the recorded price of $31.62, then one is subtracted to produce +95.4%. This does not guarantee a future return.
When was Avalyn Pharma's analyst forecast verified?
The data was verified on 2026-11-12. The dataset is valid through 2026-11-19.